Clinical note: PDF OnlyThe prognosis with postherpetic neuralgiaWatson, Peter N.C.∗,a; Watt, Verna R.a; Chipman, Maryb; Birkett, Nicholasc; Evans, Ramon J.aAuthor Information aIrene Eleanor Smythe Pain Clinic, Department of Anaesthesia, University of Toronto, Toronto, Ont.Canada, bClinical Research Support Group, Department of Epidemiology and Biostatistics, University of Toronto, Toronto, Ont.Canada cDepartment of Epidemiology and Biostatistics, University of Ottawa, Ottawa, Ont.Canada ∗Correspondence to: Christopher Peter North Watson, Assistant Professor, Department of Medicine, Irene Eleanor Smythe Pain Clinic, University of Toronto, Toronto, Ont. M5G 2C4, Canada. Submitted November 6, 1990; revised December 12, 1990; accepted March 29, 1991. Pain: August 1991 - Volume 46 - Issue 2 - p 195-199 doi: 10.1016/0304-3959(91)90076-A Buy Metrics Abstract One hundred and fifty-six patients with moderate to severe postherpetic neuralgia (PHN) were followed for up to 11 years. Nearly half of all patients were doing well at the final assessment (median 2 years) and more than half of these were on no therapy at this time. The most commonly used agents associated with a good outcome were antidepressants, topical capsaicin and analgesics of various kinds. Longer duration PHN appeared to have a worse prognosis. More of these patients were noted to be using some form of treatment at follow up. A group of patients seemed to follow a progressive course and were refractory to all treatments used in this study. © Lippincott-Raven Publishers.